InVivo Biosystems Secures New Investment to Accelerate CRISPR Innovation

InVivo Biosystems, experts in CRISPR-edited animals for biomedical discovery, today announced $3M in new investment in furtherance of the company's mission to revolutionize drug discovery leveraging its extensive intellectual property in genetically modified organisms. The Company also announced the appointment of C. Palani Palaniappan, Ph.D. to Chairman of the InVivo Biosystems Board of Directors, effective December 8, 2023.

EUGENE, Ore., Jan. 3, 2024 InVivo Biosystems, experts in CRISPR-edited animals for biomedical discovery, today announced $3M in new investment in furtherance of the company's mission to revolutionize drug discovery leveraging its extensive intellectual property in genetically modified organisms. Rogue Venture Partners led the new investment round that included Portland Seed Fund, ONAMI, and Launch Oregon to fund further CRISPR commercialization.

The Company also announced the appointment of C. Palani Palaniappan, Ph.D. to Chairman of the InVivo Biosystems Board of Directors, effective December 8, 2023. Palaniappan brings considerable experience in life science global innovation and commercialization, as well as experience on various life science corporate boards.

"The new investment in our corporate vision at a time when CRISPR's capabilities to transform therapeutic outcomes is worldwide news, will fuel existing innovation initiatives and breakthrough capabilities," said Matt Beaudet, Chief Executive Officer, InVivo Biosystems. "The financial infusion coupled with the appointment of new Board Chairman C. Palani Palaniappan puts the Company in an exciting position to make even further breakthroughs in 2024."

C. Palani Palaniappan shared his perspective on the Invivo Biosystems opportunity, "The transformative power of CRISPR in real-world applications is becoming evident through recent drug approvals in curing sickle cell anemia or many forms of blood cancer are paradigm changing concepts of 'living drugs.' InVivo's core IP and expertise in CRISPR gene engineering in model organisms are helping accelerate drug discovery with both rapid turnaround and affordability. It offers a compelling case for many biotech and pharma partners to capitalize on. I am thrilled to support the InVivo Biosystems team alongside the other accomplished board members to realize the full potential of CRISPR capabilities in revolutionizing medical innovation for the 21st Century."

Most recently InVivo Biosystems has seen its solutions validated via new technology patents and key grants for further product development.

InVivo Biosystems

Eugene, Ore.-based InVivo Biosystems, experts in CRISPR genome editing, provides end-to-end preclinical services to help pharmaceutical, nutraceutical, biotechnology companies and academic research institutions around the globe accelerate research and drug development efforts. The company's mission is to build the world's most effective genetic animal models to advance human health. With its CRISPR genome editing platform, InVivo Biosystems creates custom genome-edited C. elegans and zebrafish models for preclinical studies and drug discovery. In addition, InVivo Biosystems provides in-vivo analytical services to produce data and insights for companies to help accelerate decision-making in the early-stage development of new compounds. For more information, visit http://www.invivobiosystems.com.